Sabadello Legal advised Bausch Health Companies Inc. in connection with the spin-off of its leading eye health business into an independent publicity traded entity from the remainder of Bausch Health. The spin-off established two separate companies that include a pure-play eye-health company built on the Bausch + Lomb brand, and a pharmaceutical company focused on gastroenterology, aesthetics/dermatology, neurology and international pharmaceuticals. As part of the bifurcation of Bausch Health Ireland into two separate legal entities, Sabadello Legal was responsible for the transfer of shares in the Austrian entity.
The IPO of Bausch & Lomb is the second biggest listing in the US of 2022.1
Morgan Stanley and Goldman Sachs were serving as financial advisors; Wachtell Lipton Rosen & Katz in the United States, and Osler, Hoskin & Harcourt in Canada were acting as lead legal counsels; and Davis, Polk & Wardwell were acting as tax counsel. Sabadello Legal was acting as local counsel in Austria. The team of Sabadello Legal was led by Andreas Sabadello (Partner). Matthias Pusch (Of Counsel) was called in as advisor.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global, diversified pharmaceutical company whose mission is to improve people’s lives with its pharmaceutical products. It develops, manufactures and markets a range of products primarily in gastroenterology, neurology, dermatology and international pharmaceuticals.2
Bausch + Lomb (NYSE/TSX: BLCO), a leading global eye health business of Bausch Health Companies, Inc., is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments.3